BSE Live
Jan 21, 11:20Prev. Close
764.85
Open Price
764.00
Bid Price (Qty.)
752.85 (4)
Offer Price (Qty.)
754.60 (7)
NSE Live
Jan 21, 11:20Prev. Close
765.15
Open Price
762.45
Bid Price (Qty.)
753.50 (5)
Offer Price (Qty.)
753.95 (6)
| Key Financial Ratios of Alembic Pharmaceuticals (in Rs. Cr.) | Mar 15 | Mar 14 | Mar 13 | Mar 12 | Mar 11 | |
| Per Share Ratios | ||||||
| Basic EPS (Rs.) | 15.20 | 12.64 | 8.35 | 6.39 | 4.32 | |
| Diluted EPS (Rs.) | 15.20 | 12.64 | 8.35 | 6.39 | 4.32 | |
| Cash EPS (Rs.) | 17.56 | 14.79 | 10.21 | 8.18 | 5.89 | |
| Book Value [ExclRevalReserve]/Share (Rs.) | 44.22 | 33.40 | 24.39 | 19.14 | 14.65 | |
| Book Value [InclRevalReserve]/Share (Rs.) | 44.22 | 33.40 | 24.39 | 19.14 | 14.65 | |
| Dividend / Share(Rs.) | 3.50 | 3.00 | 2.50 | 1.40 | 1.00 | |
| Revenue from Operations/Share (Rs.) | 107.10 | 97.81 | 79.18 | 72.95 | 61.79 | |
| PBDIT/Share (Rs.) | 21.66 | 19.21 | 13.14 | 11.14 | 8.27 | |
| PBIT/Share (Rs.) | 19.31 | 17.07 | 11.28 | 9.36 | 6.70 | |
| PBT/Share (Rs.) | 19.25 | 16.55 | 10.51 | 7.96 | 5.43 | |
| Net Profit/Share (Rs.) | 15.20 | 12.64 | 8.35 | 6.39 | 4.32 | |
| Profitability Ratios | ||||||
| PBDIT Margin (%) | 20.22 | 19.64 | 16.59 | 15.27 | 13.37 | |
| PBIT Margin (%) | 18.02 | 17.44 | 14.25 | 12.82 | 10.83 | |
| PBT Margin (%) | 17.97 | 16.91 | 13.27 | 10.91 | 8.78 | |
| Net Profit Margin (%) | 14.19 | 12.92 | 10.54 | 8.76 | 6.99 | |
| Return on Networth / Equity (%) | 34.38 | 37.84 | 34.24 | 33.40 | 29.50 | |
| Return on Capital Employed (%) | 31.63 | 32.91 | 27.96 | 24.95 | 19.08 | |
| Return on Assets (%) | 18.96 | 20.49 | 15.76 | 12.16 | 9.99 | |
| Total Debt/Equity (X) | 0.20 | 0.12 | 0.31 | 0.65 | 0.99 | |
| Asset Turnover Ratio (%) | 133.60 | 158.61 | 149.46 | 138.84 | 142.78 | |
| Liquidity Ratios | ||||||
| Current Ratio (X) | 1.39 | 1.53 | 1.34 | 1.23 | 1.31 | |
| Quick Ratio (X) | 0.76 | 0.82 | 0.73 | 0.72 | 0.74 | |
| Inventory Turnover Ratio (X) | 5.28 | 5.93 | 5.59 | 5.32 | 5.31 | |
| Dividend Payout Ratio (NP) (%) | 23.02 | 23.73 | 29.93 | 21.89 | 23.12 | |
| Dividend Payout Ratio (CP) (%) | 19.93 | 20.28 | 24.49 | 17.11 | 16.96 | |
| Earnings Retention Ratio (%) | 76.98 | 76.27 | 70.07 | 78.11 | 76.88 | |
| Cash Earnings Retention Ratio (%) | 80.07 | 79.72 | 75.51 | 82.89 | 83.04 | |
| Valuation Ratios | ||||||
| Enterprise Value (Cr.) | 8,708.69 | 5,423.33 | 2,099.79 | 1,121.01 | 0.00 | |
| EV/Net Operating Revenue (X) | 4.31 | 2.94 | 1.41 | 0.82 | 0.00 | |
| EV/EBITDA (X) | 21.32 | 14.97 | 8.48 | 5.34 | 0.00 | |
| MarketCap/Net Operating Revenue (X) | 4.23 | 2.90 | 1.32 | 0.66 | 0.00 | |
| Retention Ratios (%) | 76.97 | 76.26 | 70.06 | 78.10 | 76.87 | |
| Price/BV (X) | 10.25 | 8.50 | 4.27 | 2.53 | 0.00 | |
| Price/Net Operating Revenue | 4.23 | 2.90 | 1.32 | 0.66 | 0.00 | |
| Earnings Yield | 0.03 | 0.04 | 0.08 | 0.13 | 0.00 |
17.11.2025
Alembic Pharma shares gain 2% on USFDA nod for Diltiazem Hydrochloride tablets
17.11.2025
10.11.2025
Alembic Pharma Standalone September 2025 Net Sales at Rs 1,796.24 crore, up 13.66% Y-o-Y
07.11.2025
Alembic Pharma Consolidated September 2025 Net Sales at Rs 1,910.15 crore, up 15.91% Y-o-Y
10.11.2025
Alembic Pharma Standalone September 2025 Net Sales at Rs 1,796.24 crore, up 13.66% Y-o-Y
07.11.2025
Alembic Pharma Consolidated September 2025 Net Sales at Rs 1,910.15 crore, up 15.91% Y-o-Y
12.08.2025
Alembic Pharma Consolidated June 2025 Net Sales at Rs 1,710.72 crore, up 9.54% Y-o-Y
05.08.2025
Alembic Pharma Standalone June 2025 Net Sales at Rs 1,494.17 crore, up 1.26% Y-o-Y
19.10.2021
Alembic Pharma Q2 PAT may dip 49.2% YoY to Rs 169.4 cr: ICICI Direct
13.07.2021
Alembic Pharmaceuticals Q1 PAT may dip 28.7% YoY to Rs 215 cr: KRChoksey
12.07.2021
Alembic Pharma Q1 PAT may dip 20.3% YoY to Rs 240.2 cr: ICICI Direct
18.01.2021
Alembic Pha Q3 PAT seen up 19.9% YoY to Rs. 280.9 cr: ICICI Direct